ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals,

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a

Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ:

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, I

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the a

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron

Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular

ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, wit

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR

Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market sess

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron

SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nas

Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining i

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, I

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and l

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 g

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing tr

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a

Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announc

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform

US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, R

NKE: -10% | Nike shares are trading lower after the company reported Q3 financial results. Also, the

Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result

ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 gl

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing t

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

U.S. stock futures lower, Dow down 100 points. Methanex (MEOH) shares fall 8.7% after reporting quar

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and r

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a

Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperfor

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.30) per share which beat the ana